Literature DB >> 11481522

Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas.

M R Hussein1, E Roggero, E C Sudilovsky, R J Tuthill, G S Wood, O Sudilovsky.   

Abstract

Immunoperoxidase-staining methods were used to examine the expression of hMLH1, hMSH2, and hMSH6 mismatch repair (MMR) proteins in 50 melanocytic lesions. Microsatellite instability (MSI), screened previously in these lesions by polymerase chain reaction-based microsatellite assay, showed low-level microsatellite instability (MSI-L) in 11 of 22 melanocytic dysplastic nevi (MDN) and two of nine primary cutaneous malignant melanomas (CMMs) but not in the benign melanocytic nevi (BN). Mismatch repair proteins were widely expressed in the epidermis and adnexal structures. All lesions showed positive immunoreactivity with a gradual decrease in the MMR staining values during the progression from BN to MDN to CMMs. The average percentage of positively (PP) stained cells for hMLH1, hMSH2, and hMSH6 in BN was 85.50 +/- 1.95, 77.90 +/- 4.50, and 87.11 +/- 1.85, respectively. The PP cell values in CMMs were significantly reduced as compared with BN (75.22 +/- 3.57, p= 0.01; 56.11 +/- 8.73, p= 0.02; 65.22 +/- 6.47, p = 0.0002 for hMLH1, hMSH2, and hMSH6, respectively). No comparable significant difference was found between microsatellite stable and MSI-L lesions (p = 0.173, p = 0.458, and p = 0.385), suggesting a lack of correlation between MMR expression and MMR function. There was a direct correlation between PP cell values of hMSH2 and hMSH6 (R = 0.39, p = 0.008), implying that their expression could be regulated by a common mechanism. Thus, an important finding of these studies was the reduction of MMR protein levels in CMMs; whether this reflects underlying genetic or epigenetic mechanisms is still to be determined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481522     DOI: 10.1097/00000372-200108000-00006

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  9 in total

1.  Enhancement of the repair of meniscal wounds in the red-white zone (middle third) by the injection of bone marrow cells in canine animal model.

Authors:  Mohammed Abdel-Hamid; Mahmoud R Hussein; Ahmad F Ahmad; Ebtisma M Elgezawi
Journal:  Int J Exp Pathol       Date:  2005-04       Impact factor: 1.925

Review 2.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

Review 3.  [Dysplastic melanocytic nevus].

Authors:  E Bierhoff
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

4.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

5.  Analysis of Bcl-2 protein expression in choroidal melanomas.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 6.  Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

7.  Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific.

Authors:  Qihui Jim Zhai; Daniel Gustavo Rosen; Karen Lu; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2008-01-31

Review 8.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

9.  TP53 Abnormalities and MMR Preservation in 5 Cases of Proliferating Trichilemmal Tumours.

Authors:  Raquel Martín-Sanz; José María Sayagués; Pilar García-Cano; Mikel Azcue-Mayorga; María Del Carmen Parra-Pérez; María Ángeles Pacios-Pacios; Enric Piqué-Durán; Jorge Feito
Journal:  Dermatopathology (Basel)       Date:  2021-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.